Fellow pharma powerhouse Roche has also jumped into the oral obesity arena with the $2.7 billion acquisition of Carmot Therapeutics in December 2023, giving it access to CT-388 and CT-868, both of which are dual agonists of the GLP-1 and GIP receptors with best-in-class potential for obesity, Roche said at the time
Our group now has over 800 members
Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects
All of a sudden, I show up and you see me like this, and you're like, Well, there's something going on there. There's so many things that women and men do around their looks and this is one that's still stigmatized
Levocarnitine, European Pharmacopoeia (ep) Reference Standard 138